CellAssay [3] | GW501516isdissolvedinDMSO.Cellsarestarvedbyincubationin0.2%FCSDMEMfor9h,thenpre-incubatedwithGW501516,atafinalconcentrationof2.5and5µM,or0.05%DMSOascontrolfor3hours,followedbystimulationwith150µMpalmitateboundto8.0%BSAfor12h[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. AnimalAdministration [2][3] | Rat:FemaleSpragueDawleyrats,12weeksofage,areallocatedtoasham-operatedgroupand3OVXgroups;high-doseGW501516(OVX-GW5),low-doseGW501516(OVX-GW1),andacontrolgroup(OVX-CTR),respectively.AnimalsreceiveGW501516orvehicle(methylcellulose)dailyfor4monthsbygavage.Bonemineraldensity(BMD)isassessedbydualx-rayabsorptiometryatthefemur,spine,andwholebody[2]. Mouse:Micearerandomlyallocatedtodifferentgroupsandreceivetherapeuticdietandtreatment.TheGW501516-containingrodentdietismadebyevenlyaddingGW501516tothecontroldiettoafinalconcentrationof0.04%w/w.Inthecontroldiet,10%ofthetotalcaloriesarefromfat(5.5%fromsoybeanoiland4.5%fromlard)[3]. MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References | [1].WeiZL,etal.AshortandefficientsynthesisofthepharmacologicalresearchtoolGW501516fortheperoxisomeproliferator-activatedreceptordelta.JOrgChem.2003Nov14;68(23):9116-8. [2].MostiMP,etal.Effectsoftheperoxisomeproliferator-activatedreceptor(PPAR)-δagonistGW501516onboneandmuscleinovariectomizedrats.Endocrinology.2014Jun;155(6):2178-89. [3].YangX,etal.GW501516,aPPARδagonist,amelioratestubulointerstitialinflammationinproteinurickidneydiseaseviainhibitionofTAK1-NFκBpathwayinmice.PLoSOne.2011;6(9):e25271. [4].ChenW,etal.AmetabolomicstudyofthePPARδagonistGW501516forenhancingrunningenduranceinKunmingmice.SciRep.2015May6;5:9884.
|
---|
MolecularWeight | |
---|
Formula | |
---|
CASNo. | |
---|
Storage | Powder | -20°C | 3years |
---|
| 4°C | 2years |
---|
Insolvent | -80°C | 6months |
---|
| -20°C | 1month |
---|
|
---|
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere |
---|
Solvent&Solubility | 10mMinDMSO *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.26%
品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
|
---|
|
---|
|
---|